A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice.
Virology
; 356(1-2): 147-54, 2006.
Article
em En
| MEDLINE
| ID: mdl-16938327
ABSTRACT
Rabies vaccines based on live attenuated rabies viruses or recombinant pox viruses expressing the rabies virus (RV) glycoprotein (G) hold the greatest promise of safety and efficacy, particularly for oral immunization of wildlife. However, while these vaccines induce protective immunity in foxes, they are less effective in other animals, and safety concerns have been raised for some of these vaccines. Because canine adenovirus 2 (CAV2) is licensed for use as a live vaccine for dogs and has an excellent efficacy and safety record, we used this virus as an expression vector for the RVG. The recombinant CAV2-RV G produces virus titers similar to those produced by wild-type CAV2, indicating that the RVG gene does not affect virus replication. Comparison of RVG expressed by CAV2-RV G with that of vaccinia-RV G recombinant virus (V-RG) revealed similar amounts of RV G on the cell surface. A single intramuscular or intranasal immunization of mice with CAV2-RVG induced protective immunity in a dose-dependent manner, with no clinical signs or discomfort from the virus infection regardless of the route of administration or the amount of virus.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Raiva
/
Vírus da Raiva
/
Recombinação Genética
/
Vacina Antirrábica
/
Glicoproteínas
/
Proteínas do Envelope Viral
/
Adenovirus Caninos
/
Antígenos Virais
Idioma:
En
Ano de publicação:
2006
Tipo de documento:
Article